Definium Therapeutics (DFTX) Accounts Payables (2020 - 2026)

Definium Therapeutics (DFTX) has reported Accounts Payables for 7 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 214.24% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 214.24% YoY), while the FY2025 annual figure was $5.3 million, up 166.02% from the prior year.
• Accounts Payables rose to $7.1 million in Q1 2026 per DFTX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.6 million in Q2 2023 and bottomed at $732000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $3.3 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 1071.72% — and 2024, when it plunged 72.04%.
• Definium Therapeutics' Accounts Payables stood at $2.1 million in 2022, then jumped by 95.93% to $4.1 million in 2023, then sank by 51.4% to $2.0 million in 2024, then jumped by 166.02% to $5.3 million in 2025, then surged by 33.29% to $7.1 million in 2026.
• Business Quant data shows DFTX's Accounts Payables at $7.1 million in Q1 2026, $5.3 million in Q4 2025, and $8.1 million in Q3 2025.